[go: up one dir, main page]

DK1133312T3 - Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes - Google Patents

Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes

Info

Publication number
DK1133312T3
DK1133312T3 DK00938173T DK00938173T DK1133312T3 DK 1133312 T3 DK1133312 T3 DK 1133312T3 DK 00938173 T DK00938173 T DK 00938173T DK 00938173 T DK00938173 T DK 00938173T DK 1133312 T3 DK1133312 T3 DK 1133312T3
Authority
DK
Denmark
Prior art keywords
glucagon
agonists
peptide
dependent diabetes
tzd
Prior art date
Application number
DK00938173T
Other languages
English (en)
Inventor
Lawrence E Stramm
Louis Vignati
Fatima Emitsel Yakubu-Madus
William T Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22488329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1133312(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1133312T3 publication Critical patent/DK1133312T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00938173T 1999-06-21 2000-06-06 Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes DK1133312T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13979499P 1999-06-21 1999-06-21
PCT/US2000/015548 WO2000078333A2 (en) 1999-06-21 2000-06-06 Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes

Publications (1)

Publication Number Publication Date
DK1133312T3 true DK1133312T3 (da) 2008-01-02

Family

ID=22488329

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00938173T DK1133312T3 (da) 1999-06-21 2000-06-06 Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes

Country Status (12)

Country Link
US (3) US6660716B1 (da)
EP (2) EP1849475A1 (da)
AT (1) ATE372782T1 (da)
AU (1) AU5325200A (da)
CA (1) CA2349865C (da)
CY (1) CY1106971T1 (da)
DE (1) DE60036367T2 (da)
DK (1) DK1133312T3 (da)
ES (1) ES2291210T3 (da)
PT (1) PT1133312E (da)
SI (1) SI1133312T1 (da)
WO (1) WO2000078333A2 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP2280020B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002224124A1 (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Method for producing preparation containing bioactive substance
WO2002069994A2 (en) * 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
FR2832064A1 (fr) * 2001-11-13 2003-05-16 Lipha Composition pharmaceutique comprenant une glitazone et un derive de thiazolidinedione et son utilisation pour traiter le diabete
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
ES2259736T3 (es) * 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US8372804B2 (en) * 2007-10-24 2013-02-12 Mannkind Corporation Delivery of active agents
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602005008497D1 (de) * 2004-03-15 2008-09-11 Roche Diagnostics Gmbh Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
EA011168B1 (ru) 2004-04-23 2009-02-27 Конджачем Биотекнолоджис Инк. Способ очистки конъюгатов альбумина
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
WO2007115131A2 (en) * 2006-03-29 2007-10-11 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including other ingredient(s)
MX381952B (es) 2005-09-14 2025-03-13 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
JP5599975B2 (ja) 2006-02-22 2014-10-01 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
GEP20125410B (en) * 2007-02-01 2012-02-27 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
DK2211842T3 (da) * 2007-10-24 2015-09-21 Mannkind Corp En inhalerbar tørpulverformulering omfattende glp-1 til anvendelse i behandlingen af hyperglykæmi og diabetes ved pulmonær administration
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
TW200932223A (en) * 2007-12-13 2009-08-01 Univ Kyushu Nat Univ Corp Drug-containing nanoparticles
KR101762089B1 (ko) 2008-06-13 2017-07-26 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
BRPI1009619B8 (pt) * 2009-06-05 2021-05-25 Veroscience Llc forma de dosagem farmacêutica
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
MX2011013312A (es) 2009-06-12 2012-01-25 Mankind Corp Microparticulas de dicetopiperazina con areas de superficie especificas definidas.
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
KR20150013838A (ko) 2012-05-17 2015-02-05 트랜스테크 파르마 엘엘씨 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN118903385A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349352A (en) * 1980-08-14 1982-09-14 Rockefeller University Test for glucosylated hemoglobin and other glucosylated proteins
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6329403B1 (en) 1998-06-30 2001-12-11 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes

Also Published As

Publication number Publication date
US7223728B2 (en) 2007-05-29
US6660716B1 (en) 2003-12-09
WO2000078333A3 (en) 2001-07-12
EP1133312B8 (en) 2007-10-17
DE60036367D1 (de) 2007-10-25
AU5325200A (en) 2001-01-09
CY1106971T1 (el) 2012-09-26
ATE372782T1 (de) 2007-09-15
WO2000078333A2 (en) 2000-12-28
DE60036367T2 (de) 2008-05-29
CA2349865C (en) 2014-08-19
EP1133312A2 (en) 2001-09-19
SI1133312T1 (sl) 2008-02-29
ES2291210T3 (es) 2008-03-01
USRE40876E1 (en) 2009-08-18
PT1133312E (pt) 2007-11-30
EP1133312B1 (en) 2007-09-12
CA2349865A1 (en) 2000-12-28
EP1849475A1 (en) 2007-10-31
US20040127414A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
DK1133312T3 (da) Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
DK1181043T3 (da) Anvendelse af exendiner og agonister dertil til behandling af svangerskabsdiabetes mellitus
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
Deacon et al. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon Circulation and degradation of GIP and GLP-1
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
MX2008002370A (es) Exendina para tratar la diabetes y reducir el peso del cuerpo.
NO20064929L (no) Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
Bolli et al. Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
EA200800198A1 (ru) Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
MX2007012102A (es) Control superior de glucosa en la sangre en tratamiento de diabetes.
NO331089B1 (no) Sammensetning omfattende en GPR119-agonist og en DPP-IV-inhibitor samt fremgangsmate for fremstilling av slike.
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
AR026356A1 (es) Metodo para tratar la diabetes
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
NZ602583A (en) Methods of using diacerein as an adjunctive therapy for diabetes
Yamamoto et al. Clinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors: a case report
NO996270L (no) Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor